Navigation Links
AcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results
Date:5/8/2012

clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office.  A fourth product candidate, ARX-04, is a sufentanil product for the treatment of moderate-to-severe acute pain, and AcelRx plans to initiate a Phase 2 study funded by a grant from USAMRMC, contingent on approval of the proposed clinical protocol for the study by USAMRMC.

Forward Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to AcelRx Pharmaceuticals' financial viability, anticipated increases in research and development and general and administrative expenses, the sufficiency of funds to support its clinical trials and operations, planned or anticipated future clinical development of AcelRx Pharmaceuticals' product candidates, including the anticipated timing for clinical trials, progress towards initiation of the remaining Phase 3 study for ARX-01 and the Phase 2 study for ARX-04, and the therapeutic and commercial potential of AcelRx Pharmaceuticals' product candidates.  These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties.  AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of AcelRx Pharmaceuticals' product development activities and clinical trials; the uncertain clinical development process, including the risk that planned clinical trials may not begin on time, have an effective design, enroll a sufficient number of patients, or be initiated or completed on schedule, if at all; any delays or inability to obtain, regulatory approval of its
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
3. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
4. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
6. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
7. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
8. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
9. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
11. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... ZIONA, Israel , June 29, ... BVXV, TASE: BVXV) today announced positive preliminary results from ... candidate for a universal influenza vaccine. In this trial, ... of 50 to 65, followed by an administration of ... later. M-001 was found to be safe and well ...
(Date:6/29/2015)... Calif. , June 29, 2015  Isis Pharmaceuticals, ... has been added to the Russell 1000 Index, effective ... performance of the large-cap segment of the U.S. equity ... Index and includes approximately 1000 of the largest securities ... current index membership. "We are pleased to ...
(Date:6/29/2015)... Calif. , June 29, 2015  Arbor ... medical workstation lineup. The high-powered, multi-functional M2150 ... generation Intel® Haswell Core i5-4402E 1.6 ... provide significant data processing and computing performance. Integrated ... making the unit well suited for graphics-intense applications ...
Breaking Medicine Technology:BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... , CHEYENNE, Wyo., Aug. 24 The ... of its Pay-for-Participation (P4P) program, a component of its innovative ... collaboration between the practitioner community and the Wyoming EqualityCare (EC) ... Wyoming Medicaid members. , , (Logo: ...
... Curemark Founder and CEO Dr. Joan Fallon delivered the ... Conference at Harvard Medical School on July 14th. , ... conclave is particularly significant, since epigenetics is the study of ... in the DNA sequence. Presenters at the session showcased many ...
Cached Medicine Technology:Wyoming Department of Health's Pay-for-Participation Program Reports Positive Clinical Outcomes 2Wyoming Department of Health's Pay-for-Participation Program Reports Positive Clinical Outcomes 3Curemark CEO Presents at Epigenomics Conference 2
(Date:6/29/2015)... (PRWEB) , ... June 29, 2015 , ... ... have developed a new approach to build nearly complete genomes by combining high-throughput ... of genomic variation, critically important for their association with human disease, but previously ...
(Date:6/29/2015)... (PRWEB) , ... June 29, 2015 , ... ... to healthcare providers for patients with certain neuropsychiatric and chronic pain conditions, has ... and CEO. , The appointments include: Peter Donato, Senior Vice President, Chief Financial ...
(Date:6/29/2015)... ... ... OR Manager announced Monday the launch of an enhanced http://www.ormanager.com . The ... and weekly eLetter. The website contains the same informational articles, products, and resources that ... , In addition to a refreshed look, http://www.ormanager.com now provides users with ...
(Date:6/29/2015)... York, NY (PRWEB) , ... June 29, 2015 ... ... dietary supplement with Citicoline (Cognizin®) from Kyowa Hakko Bio to French consumers. , ... the macular cells from oxidative stress caused by free radicals. In addition to ...
(Date:6/29/2015)... ... June 29, 2015 , ... FACE is proud to be one of ... reduction of the double chin and redefining of the jawline. Excess fat under ... older and heavier causing the person distress and poor self-image. , Kybella was produced ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 2Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 4Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 2Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 3Health News:OR Manager Launches New Website 2Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 2Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 3Health News:FACE Detroit Skin and Wellness Clinic Introduces Newly FDA Approved Kybella for the elimination of the Double Chin. 2
... ... Best Nursing Homes” List , ... Tucson, Ariz. (Vocus) February 2, 2010 -- A Tucson retirement community’s health ... by U.S. News and World Report. The designation will appear in the national magazine’s ...
... , INDIANAPOLIS , Feb. 2 ... senior management is scheduled to present at the UBS 20th Annual ... 8:00 a.m. Eastern Standard Time .   , All interested ... by visiting www.wellpoint.com and selecting the "Investor ...
... the University of Pennsylvania School of Medicine have found ... a toxic form of the same protein. The protein, ... that are the hallmarks of Parkinson,s disease, Alzheimer,s disease, ... molecular link between the presence of inclusions and neuronal ...
... study found , TUESDAY, Feb. 2 (HealthDay News) -- ... who are at risk for kidney failure and associated problems, ... in the Feb. 3 issue of the Journal of ... for protein levels in urine (proteinuria) be incorporated into upcoming ...
... , SOMERSET, N.J. , Feb. 2 ... logistical staffing provider serving the Federal Government, today announced that it ... the Company has regained compliance with the $1.00 per ... Nasdaq Capital Market, pursuant to the Nasdaq Marketplace Rules. In the ...
... link between MMR vaccine, developmental disorder , TUESDAY, ... journal The Lancet on Tuesday formally retracted ... mumps and rubella vaccine to autism and gastrointestinal problems. ... 1998, set off a worldwide furor, with many researchers ...
Cached Medicine News:Health News:U.S. News & World Report Ranks Sonora at Splendido Among Top in Nation 2Health News:WellPoint Announces Appearance at Upcoming Conference 2Health News:WellPoint Announces Appearance at Upcoming Conference 3Health News:3 brain diseases linked by toxic form of same neural protein 2Health News:Protein Levels in Urine Help Predict Kidney Function 2Health News:Protein Levels in Urine Help Predict Kidney Function 3Health News:TeamStaff Regains Compliance with Nasdaq $1.00 Minimum Bid Rule 2Health News:TeamStaff Regains Compliance with Nasdaq $1.00 Minimum Bid Rule 3Health News:Controversial Autism Study Retracted by Medical Journal 2Health News:Controversial Autism Study Retracted by Medical Journal 3Health News:Controversial Autism Study Retracted by Medical Journal 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: